Claims
- 1. An isolated nucleic acid segment comprising a full length sequence or the fill length complement of a sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:83 and SEQ ID NO:85.
- 2. An isolated nucleic acid molecule, of a size between about 14 and 100 bases in length, identical in sequence to a contiguous portion of at least 14 bases of a nucleic acid or its complement selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:83 and SEQ ID NO:85.
- 3. The isolated nucleic acid molecule of claim 2, of a size of between about 17 and 100 bases in length.
- 4. The isolated nucleic acid molecule of claim 2, of a size of between about 20 and 100 bases in length.
- 5. The isolated nucleic acid molecule of claim 2, of a size of between about 25 and 100 bases in length.
- 6. The isolated nucleic acid molecule of claim 2, of a size of between about 30 and 100 bases in length.
- 7. The isolated nucleic acid according to claim 1, wherein the sequence is SEQ ID NO:1.
- 8. The isolated nucleic acid according to claim 1, wherein the sequence is SEQ ID NO:2.
- 9. The isolated nucleic acid according to claim 1, wherein the sequence is SEQ ID NO:3.
- 10. The isolated nucleic acid according to claim 1 wherein the sequence is SEQ ID NO:4.
- 11. The isolated nucleic acid according to claim 1, wherein the sequence is SEQ ID NO:5.
- 12. The isolated nucleic acid according to claim 1, wherein the sequence is SEQ ID NO:10.
- 13. The isolated nucleic acid according to claim 1 wherein the sequence is SEQ ID NO:11.
- 14. The isolated nucleic acid according to claim 1, wherein the sequence is SEQ ID NO: 12.
- 15. The isolated nucleic acid according to claim 1, wherein the sequence is SEQ ID NO:13.
- 16. The isolated nucleic acid according to claim 1, wherein the sequence is SEQ ID NO:15.
- 17. The isolated nucleic acid according to claim 1, wherein the sequence is SEQ ID NO:16.
- 18. The isolated nucleic acid according to claim 1, wherein the sequence is SEQ ID NO:17.
- 19. The isolated nucleic acid according to claim 1, wherein the sequence is SEQ ID NO: 19.
- 20. The isolated nucleic acid according to claim 1, wherein the sequence is SEQ ID NO:20.
- 21. The isolated nucleic acid according to claim 1, wherein the sequence is SEQ ID NO:21.
- 22. The isolated nucleic acid according to claim 1, wherein the sequence is SEQ ID NO:22.
- 23. The isolated nucleic acid according to claim 1, wherein the sequence is SEQ ID NO:23.
- 24. The isolated nucleic acid according to claim 1 wherein the sequence is SEQ ID NO:45.
- 25. The isolated nucleic acid according to claim 1, wherein the sequence is SEQ ID NO:46.
- 26. The isolated nucleic acid according to claim 1 wherein the sequence is SEQ ID NO:83.
- 27. The isolated nucleic acid according to claim 1, wherein the sequence is SEQ ID NO:85.
- 28. An isolated polypeptide with an amino acid sequence encoded by a polynucleotide having a sequence selected from a group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:45 and SEQ ID NO:46.
- 29. An isolated peptide, of a size between 10 and 50 amino acids in length, with an amino acid sequence encoded within a polynucleotide having a sequence selected from a group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:45 and SEQ ID NO:46.
- 30. A method for identifying markers for human prostate cancer, comprising the following steps:
a) providing human prostate RNAs; b) amplifying said RNAs to provide nucleic acid amplification products; c) separating said nucleic acid amplification products; and d) identifying those RNAs that are differentially expressed between human prostate cancers versus normal or benign human prostate.
- 31. The method according to claim 30, further comprising converting said RNAs into cDNAs using reverse transcriptase prior to amplification.
- 32. The method according to claim 31, further comprising amplifying the cDNAs by polymerase chain reaction (PCR) using arbitrarily chosen oligonucleotide primers under initially reduced stringency conditions.
- 33. The method according to claim 31, further comprising:
a) using one oligo dT anchoring primer and an arbitrarily chosen oligonucleotide primer for the reverse transcription step; and b) using an oligo dT anchoring primer and an arbitrarily chosen oligonucleotide primer for the amplification step.
- 34. A method for detecting prostate cancer cells in a biological sample comprising the step of detecting a prostate cancer marker in said sample, wherein said prostate cancer marker is a nucleic acid having a sequence selected from a group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:83 and SEQ ID NO: 85.
- 35. The method of claim 34, further comprising the steps of
a) providing nucleic acids from said sample; b) amplifying said nucleic acids to form nucleic acid amplification products; c) contacting said nucleic acid amplification products with an oligonucleotide probe that will hybridize under stringent conditions with said prostate cancer marker; d) detecting the nucleic acid amplification products which hybridize with said probe; and e) measuring the amount of said nucleic acid amplification products that hybridize with said probe.
- 36. The method of claim 35, in which said oligonucleotide probe is selected to bind specifically an isolated nucleic acid having a sequence selected from a group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:83 and SEQ ID NO:85.
- 37. The method of claim 35, in which the sequence of said oligonucleotide probe is selected to bind specifically to a nucleic acid product of a known gene, said nucleic acid product selected from a group consisting of cyclin A (SEQ ID NO:8), fibronectin (SEQ ID NO:7), and a truncated form of Her2/neu (SEQ ID NO:9).
- 38. The method of claim 35, in which the sequence of said oligonucleotide probe is selected to bind specifically to a truncated nucleic acid product of the Her2/neu gene.
- 39. The method of claim 35, in which the sequence of said oligonucleotide probe is selected to bind specifically to a nucleic acid product of the cyclin A gene.
- 40. The method of claim 35, in which the sequence of said oligonucleotide probe is selected to bind specifically to a nucleic acid product of the fibronectin gene.
- 41. The method of claim 34, further comprising the steps of
a) providing nucleic acids from said sample; b) providing primers that will selectively amplify said prostate cancer marker; c) amplifying said nucleic acids with said primers to form nucleic acid amplification products; d) detecting said nucleic acid amplification products; and e) quantifying said nucleic acid amplification products.
- 42. The method of claim 41, wherein said primers are selected to amplify a nucleic acid having a sequence selected from a group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:83 and SEQ ID NO:85.
- 43. The method of claim 41, wherein said primers are selected to amplify a nucleic acid product of a known gene, said nucleic acid product selected from a group consisting of cyclin A, fibronectin, and a truncated form of Her2/neu.
- 44. The method of claim 41, wherein said primers are selected to amplify a truncated nucleic acid product of the Her2/neu gene.
- 45. The method of claim 41, wherein said primers are selected to amplify a nucleic acid product of the cyclin A gene.
- 46. The method of claim 41, wherein said primers are selected to amplify a nucleic acid product of the fibronectin gene.
- 47. The method of claim 41, further comprising determining the prognosis of prostate cancer patients by quantifying the nucleic acid amplification product binding to a probe specific for said prostate cancer marker.
- 48. The method of claim 41, further comprising determining the diagnosis of human prostate cancer by quantifying the nucleic acid amplification product binding to a probe specific for said prostate cancer marker.
- 49. The method of claim 41, further comprising determining the prognosis of prostate cancer patients by quantifying the nucleic acid amplification product.
- 50. The method of claim 41, further comprising determining the diagnosis of human prostate cancer by quantifying the nucleic acid amplification product.
- 51. A method of treating individuals with prostate cancer, comprising the steps of:
a) obtaining a sample of tissue from an individual with prostate cancer; b) screening said sample for the expression of a polypeptide encoded by a polynucleotide having a sequence selected from a group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:83 and SEQ ID NO:85; c) providing an antibody that reacts immunologically against said polypeptide; and d) administering an effective amount of said antibody to an individual with prostate cancer.
- 52. A method of treating individuals with prostate cancer, comprising the steps of:
a) obtaining a sample of tissue from an individual with prostate cancer; b) screening said sample for the expression of a polynucleotide having a sequence selected from a group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5,, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:83 and SEQ ID NO:85; c) providing an antisense DNA molecule that encodes an RNA molecule that binds to said polynucleotide; d) providing said antisense DNA molecule in the form of a human vector containing appropriate regulatory elements for the production of said RNA molecule; and e) administering an effective amount of said vector to an individual with prostate cancer.
- 53. A kit for use in detecting prostate cancer cells in a biological sample, comprising:
(a) a primer pair for amplifying a nucleic acid having a sequence selected from a group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:83 and SEQ ID NO:85; and (b) containers for each of said primers.
- 54. A kit for use in detecting prostate cancer cells in a biological sample, comprising:
(a) a primer pair for amplifying a nucleic acid product of a human gene, said nucleic acid product selected from a group consisting of cyclin A, fibronectin, and a truncated form of Her2/neu; and (b) containers for each of said primers.
- 55. A kit for use in detecting prostate cancer cells in a biological sample, comprising:
(a) an oligonucleotide probe which binds under high stringency conditions to an isolated nucleic acid having a sequence selected from a group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:83 and SEQ ID NO:85; and (b) a container for said probe.
- 56. A kit for use in detecting prostate cancer cells in a biological sample, comprising:
(a) an oligonucleotide probe which binds under high stringency conditions to a nucleic acid product of a human gene, said nucleic acid product selected from a group consisting of cyclin A, fibronectin gene, and a truncated form of Her2/neu; and (b) a container for said probe.
- 57. A kit for use in detecting prostate cancer cells in a biological sample, comprising:
(a) an antibody which binds immunologically to a protein having an amino acid sequence encoded by a nucleic acid sequence selected from a group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:83 and SEQ ID NO:85; and (b) a container for said antibody.
- 58. A method for detecting prostate cancer cells in biological samples, comprising the following steps:
(a) providing an antibody that binds immunologically to a peptide, said peptide encoded by an isolated nucleic acid selected from a group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:83 and SEQ ID NO:85, cyclin A, fibronectin, and a truncated form of Her2/neu; (b) contacting a human tissue sample with said antibody; (c) separating antibody bound to said tissue sample from unbound antibody; and (d) detecting the bound antibody.
- 59. A kit for use in detecting prostate cancer cells in a biological sample, comprising:
(a) an antibody which binds immunologically to a polypeptide having an amino acid sequence encoded by a nucleic acid selected from a group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:83 and SEQ ID NO:85, cyclin A, fibronectin, and a truncated form of Her2/neu; and (b) a container for said antibody.
- 60. A method for treating individuals with prostate cancer, comprising the following steps:
(a) selecting a prostate cancer marker from a group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:83, SEQ ID NO:85, cyclin A, fibronectin, and a truncated form of Her2/neu; (b) providing an inhibitor designed to bind specifically to the protein product of said prostate cancer marker; and (c) administering an effective dosage of said inhibitor to a prostate cancer patient.
- 61. An isolated nucleic acid segment useful as a marker of bladder cancer or breast cancer and having a sequence or the full length complement of a sequence selected from the group consisting of SEQ ID NO:3, SEQ ID NO:83 and SEQ ID NO:85.
- 62. An isolated nucleic acid molecule, of a size between about 14 and 100 bases in length, identical in sequence to a contiguous portion of at least 14 bases of a nucleic acid or its complement selected from the group consisting of SEQ ID NO:3, SEQ ID NO:83 and SEQ ID NO:85.
- 63. An isolated polypeptide with an amino acid sequence encoded by a nucleic acid having a sequence selected from a group consisting of SEQ ID NO:3, SEQ ID NO:83 and SEQ ID NO:85.
- 64. An isolated peptide, of a size between 10 and 50 amino acids in length, with an amino acid sequence encoded within a polynucleotide having a sequence selected from a group consisting of SEQ ID NO:3, SEQ ID NO:83 and SEQ ID NO:85.
- 65. A method for detecting bladder cancer or breast cancer cells in a biological sample comprising the step of detecting a bladder cancer or breast cancer marker in said sample, wherein said bladder cancer or breast cancer marker is a nucleic acid having a sequence selected from a group consisting of SEQ ID NO:3, SEQ ID NO:83 and SEQ ID NO:85.
- 66. The method of claim 65, further comprising the steps of
a) providing nucleic acids from said sample; b) amplifying said nucleic acids to form nucleic acid amplification products; c) contacting said nucleic acid amplification products with an oligonucleotide probe that will hybridize under stringent conditions with said bladder cancer or breast cancer marker; d) detecting the nucleic acid amplification products which hybridize with said probe; and e) quantifying the nucleic acid amplification products that hybridize with said probe.
- 67. The method of claim 65, further comprising the steps of
a) providing nucleic acids from said sample; b) providing primers that will selectively amplify said bladder cancer or breast cancer marker; c) amplifying said nucleic acids with said primers to form nucleic acid amplification products; d) detecting said nucleic acid amplification products; and e) quantifying said nucleic acid amplification products.
- 68. The method of claim 65, further comprising determining the prognosis of bladder cancer or breast cancer patients by quantifying the nucleic acid amplification product binding to a probe specific for said bladder cancer or breast cancer marker.
- 69. The method of claim 65, further comprising determining the diagnosis of human bladder cancer or breast cancer by quantifying the nucleic acid amplification product binding to a probe specific for said bladder cancer or breast cancer marker.
- 70. The method of claim 65, further comprising determining the prognosis of bladder cancer or breast cancer patients by quantifying the nucleic acid amplification product.
- 71. The method of claim 65, further comprising determining the diagnosis of human bladder cancer or breast cancer by quantifying the nucleic acid amplification product.
- 72. A method of treating individuals with bladder cancer or breast cancer, comprising the steps of:
a) obtaining a sample of tissue from an individual with bladder cancer or breast cancer; b) screening said sample for the expression of a polypeptide encoded by a polynucleotide having a sequence selected from a group consisting of SEQ ID NO:3, SEQ ID NO:83 and SEQ ID NO:85; c) providing an antibody that reacts immunologically against said polypeptide; and d) administering an effective amount of said antibody to an individual with bladder cancer or breast cancer.
- 73. A method of treating a subject with bladder cancer or breast cancer, comprising the steps of:
a) obtaining a sample of tissue from an individual with bladder cancer or breast cancer; b) screening said sample for the expression of a polynucleotide having a sequence selected from a group consisting SEQ ID NO:3, SEQ ID NO:83 and SEQ ID NO:85; c) providing an antisense DNA molecule that encodes an RNA molecule that binds to said polynucleotide; d) providing said antisense DNA molecule in the form of a human vector containing appropriate regulatory elements for the production of said RNA molecule; and e) administering an effective amount of said vector to an individual with bladder cancer or breast cancer.
- 74. A kit for use in detecting bladder cancer cells or breast cancer cells in a biological sample, comprising:
a) a primer pair for amplifying a nucleic acid having a sequence selected from a group consisting of SEQ ID NO:3, SEQ ID NO:83 and SEQ ID NO:85; and b) containers for each of said primers.
- 75. A kit for use in detecting bladder cancer cells or breast cancer cells in a biological sample, comprising:
a) an oligonucleotide probe which binds under high stringency conditions to an isolated nucleic acid having a sequence selected from a group consisting of SEQ ID NO:3, SEQ ID NO:83 and SEQ ID NO:85; and b) a container for said probe.
- 76. A kit for use in detecting bladder cancer cells or breast cancer cells in a biological sample, comprising:
a) an antibody which binds immunologically to a protein having an amino acid sequence encoded by a polynucleotide having a sequence selected from a group consisting of SEQ ID NO:3, SEQ ID NO:83 and SEQ ID NO:85; and b) a container for said antibody.
- 77. A method for detecting bladder cancer cells or breast cancer cells in biological samples, comprising the following steps:
a) providing an antibody that binds immunologically to a polypeptide encoded by an isolated nucleic acid selected from a group consisting of SEQ ID NO:3, SEQ ID NO:83 and SEQ ID NO:85; b) contacting a human tissue sample with said antibody; c) separating antibody bound to said tissue sample from unbound antibody; and d) detecting the bound antibody.
Parent Case Info
[0001] The present application is a continuation-in-part of co-pending U.S. patent application Ser. No. 08/692,787 filed Jul. 31, 1996. The entire text of the above-referenced disclosure is specifically incorporated by reference herein without disclaimer.
Divisions (2)
|
Number |
Date |
Country |
Parent |
09662270 |
Sep 2000 |
US |
Child |
09974546 |
Oct 2001 |
US |
Parent |
09097199 |
Jun 1998 |
US |
Child |
09662270 |
Sep 2000 |
US |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
08692787 |
Jul 1996 |
US |
Child |
09097199 |
Jun 1998 |
US |